SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kimia Biosciences gets permission to manufacture, sell new API ‘Brivaracetam’

23 Feb 2021 Evaluate

Kimia Biosciences has been granted permission to manufacture new API for sale or for distribution namely Brivaracetam by Central Drugs Standard Control Organization, Ministry of Health & Family Welfare, FDA Bhawan, New Delhi, dated February 15, 2021 in FORM CT-22 under Drugs & Cosmetics Acts & Rules thereunder. 

Kimia Biosciences is a pharmaceutical company and the state of the art manufacturing facility is manufacturing latest Bulk Drugs and intermediates (R&D based) for India and Overseas markets.

Kimia Biosciences Share Price

38.01 0.33 (0.88%)
17-Apr-2026 14:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.90
Dr. Reddys Lab 1229.80
Cipla 1236.25
Zydus Lifesciences 944.20
Lupin 2313.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×